The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for November 2023 (PDF).
This issue raises awareness that falsified Ozempic® and Saxenda® products have been found in the UK, including falsified pens containing insulin, which may lead to patient harm. Clinicians should be vigilant for symptoms linked to hypoglycaemia in patients who may have obtained a falsified product. Yellow Cards can be submitted and such products should be quarantined if possible. Patients who are concerned that the pens they have purchased might be falsified that they should not use the pens and report as a Yellow Card as well.
Clinicians involved in the prescription and supply of the COVID-19 treatment Paxlovid® (nirmatrelvir and ritonavir) are reminded of the risk of harmful drug interactions with the ritonavir component due to its inhibition of the enzyme CYP3A. As such it can interact with many commonly prescribed drugs. Prescribers should obtain a detailed patient history of current medications before prescribing.
Finally this month, healthcare professionals are reminded to remain vigilant for suspected adverse reactions and safety concerns associated with e-cigarettes and e-liquids, commonly known as vapes. Suspected adverse reactions should be reported to the Yellow Card scheme and patients should be encouraged to raise any safety concerns with a healthcare professional and can self-report using the Yellow Card scheme.
Lastly in this issue is a summary of letters to healthcare professionals in October. These generally related to supply issues and recalls.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.